|4.8 -0.19 (-3.81%)||12-08 16:00|
|Targets||6-month :||6.38||1-year :||7.46|
|Resists||First :||5.46||Second :||6.38|
|Supports||First :||4.17||Second :||3.38|
|MAs||MA(5) :||4.98||MA(20) :||4.72|
|MA(100) :||3.16||MA(250) :||2.56|
|MACD||MACD :||0.3||Signal :||0.3|
|%K %D||K(14,3) :||60.4||D(3) :||66.6|
|52-week||High :||5.46||Low :||1.28|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMMX ] has closed above bottom band by 46.5%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||5.03 - 5.06||5.06 - 5.08|
|Low:||4.6 - 4.63||4.63 - 4.66|
|Close:||4.75 - 4.8||4.8 - 4.84|
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||20 (M)|
|Shares Float||8 (M)|
|Held by Insiders||53.4 (%)|
|Held by Institutions||2.2 (%)|
|Shares Short||243 (K)|
|Shares Short P.Month||172 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-45.7 %|
|Return on Equity (ttm)||-78.3 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-13 (M)|
|Levered Free Cash Flow||-7 (M)|
|Price to Book value||4.75|
|Price to Sales||0|
|Price to Cash Flow||-7.57|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|